Medannex Ltd

New data released today by the BIA and Clarivate reveals that 2021 is on track to be another record-breaking year for UK biotech investment. More than £830m in fresh capital was raised in the first quarter, almost matching the £894m raised in the first half of 2020, which itself was a record-breaking year.

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Medannex's novel therapy MDX-124, for the treatment of biliary tract cancer (BTC). The FDA’s decision is based on emerging clinical data from the ongoing first-in-human Phase 1b ATTAINMENT clinical trial, which shows promising efficacy signals in patients treated with MDX-124 monotherapy. Durable disease control and tumour shrinkage have been observed in several BTC patients, with no significant side effects. 

Medannex will work in close collaboration with senior scientists at ARU (Cambridge) and world-leading paediatric oncologists to deliver this important project. MDX-124 is the first clinic-ready agent to target annexin-A1, a protein known to drive numerous cancers and other diseases. In preclinical tests, MDX-124 has been shown to stop the growth and spread of certain cancers, as well as harnessing the immune system to attack tumours. MDX-124 is currently being evaluated in a first-in-human Phase 1b oncology study in adults (‘ATTAINMENT’). Recent data mining of a paediatric genomics database and staining of tumour tissue revealed that annexin-A1 is highly expressed in osteosarcoma, making MDX-124 a strong candidate to treat this disease.